Ernexa Therapeutics Inc. (ERNAW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 2.5M 5M 7.5M Q1 '10: 6.3M Q2 '10: 6.2M Q3 '10: 6.5M Q4 '10: 6.3M Q1 '11: 6M Q2 '11: 6.1K Q3 '11: 5.9M Q4 '11: 6.1M Q1 '12: 6.1M Q2 '12: 6K Q3 '12: 6M Q4 '12: 5.9M Q1 '13: 6.1M Q2 '13: 5.5M Q3 '13: 5.5M Q4 '13: 6.6M Q1 '14: 6.4M Q2 '14: 6.9M Q3 '14: 6M Q4 '14: 6.8M Q1 '15: 5.7M Q2 '15: 6.2M Q3 '15: 6.1M Q4 '15: 6.5M Q1 '16: 5.5M Q2 '16: 5.4M Q3 '16: 5.4M Q4 '16: 6M Q1 '17: 5.2M Q2 '17: 5.5M Q3 '17: 5.2M Q4 '17: 5.3M Q1 '18: 5.8M Q2 '18: 5.7M Q3 '18: 6M Q4 '18: 5.9M Q1 '19: 4.8M Q2 '19: 5.2M Q3 '19: 4.6M Q4 '19: 5.2M Q1 '20: 2.4M Q2 '20: 754K Q3 '20: 1.5M Q4 '20: 1.2M Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 51K Q4 '23: 17K Q1 '24: 47K Q2 '24: 47K Q3 '24: 487K Q4 '24: 1K Q1 '11 Q4 '12 Q3 '14 Q2 '16 Q1 '18 Q4 '19 Q1 '23 Q4 '24

Gross Profit Quarterly

-200K 0 200K 400K 600K Q3 '22: 0 Q4 '22: 0 Q1 '23: -50K Q2 '23: 0 Q3 '23: -69K Q4 '23: -49K Q1 '24: -14K Q2 '24: -48K Q3 '24: 547K Q4 '24: 1K Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q2 '10: -407K Q3 '10: 155K Q1 '11: -520K Q2 '11: -1.1M Q3 '11: -795K Q4 '11: -908K Q1 '12: -997K Q2 '12: -643K Q3 '12: 99K Q4 '12: 479K Q1 '13: -366K Q2 '13: -115K Q3 '13: -236K Q4 '13: -402K Q1 '14: -654K Q2 '14: -1.3M Q3 '14: -1.3M Q4 '14: -1.5M Q1 '15: -2.2M Q2 '15: -2.5M Q3 '15: -1.3M Q4 '15: -903K Q1 '16: -868K Q2 '16: -696K Q3 '16: -414K Q4 '16: -300K Q1 '17: -834K Q2 '17: -26K Q3 '17: -53K Q4 '17: -489K Q1 '18: -313K Q2 '18: -27K Q3 '18: 370K Q4 '18: 173K Q1 '19: -217K Q2 '19: -2K Q3 '19: -316K Q4 '19: -1.2M Q1 '20: -1M Q2 '20: -2M Q3 '20: -2M Q4 '20: -2.2M Q1 '21: -8.9M Q2 '21: -10M Q3 '21: -86.3M Q4 '21: -8.5M Q1 '22: -6.3M Q2 '22: -13.9M Q3 '22: -8.3M Q4 '22: -4.7M Q1 '23: -5.3M Q2 '23: -4.5M Q3 '23: -5.5M Q4 '23: -5.8M Q1 '24: -5.8M Q2 '24: -4.9M Q3 '24: -2.3M Q4 '24: -2.7M Q1 '25: -2.7M Q2 '25: -2.5M Q3 '25: -2M Q4 '25: -2.1M Q1 '26: -5.6M Q2 '26: -4.1M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q2 '10: -457K Q3 '10: 124K Q1 '11: -559K Q2 '11: -984K Q3 '11: -837K Q4 '11: -1M Q1 '12: -1M Q2 '12: -633K Q3 '12: 54K Q4 '12: 629K Q1 '13: -369K Q2 '13: -99K Q3 '13: -234K Q4 '13: -351K Q1 '14: -649K Q2 '14: -1.3M Q3 '14: -1.3M Q4 '14: -1.7M Q1 '15: -2.3M Q2 '15: -2.6M Q3 '15: -1.3M Q4 '15: -990K Q1 '16: -1M Q2 '16: -850K Q3 '16: -573K Q4 '16: -459K Q1 '17: -90K Q2 '17: -164K Q3 '17: -184K Q4 '17: -639K Q1 '18: -409K Q2 '18: -124K Q3 '18: 222K Q4 '18: 52K Q1 '19: -313K Q2 '19: -90K Q3 '19: -351K Q4 '19: -1.3M Q1 '20: -1M Q2 '20: -2M Q3 '20: -2M Q4 '20: -2.2M Q1 '21: -18.5M Q2 '21: -10.1M Q3 '21: -86M Q4 '21: -8M Q1 '22: -9.4M Q2 '22: -3.4M Q3 '22: -7.3M Q4 '22: -4.5M Q1 '23: -5.4M Q2 '23: -4.5M Q3 '23: -5.6M Q4 '23: -6.2M Q1 '24: -6.6M Q2 '24: -5.5M Q3 '24: -26.6M Q4 '24: -5.8M Q1 '25: -8.2M Q2 '25: -3.1M Q3 '25: -1.2M Q4 '25: -1.5M Q1 '26: -5.5M Q2 '26: -4M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue Quarterly

-100K -50K 0 50K 100K 150K Q3 '22: 0 Q4 '22: 0 Q1 '23: 50K Q2 '23: 0 Q3 '23: 120K Q4 '23: 66K Q1 '24: 61K Q2 '24: 95K Q3 '24: -60K Q4 '24: 0 Q2 '25: 0 Q2 '26: 0 Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '26

Operating Cash Flow Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q3 '10: 1.3M Q4 '10: 628K Q1 '11: 904K Q2 '11: -85K Q3 '11: -118K Q4 '11: -127K Q1 '12: 255K Q2 '12: 342K Q3 '12: 397K Q4 '12: 1.2M Q1 '13: 166K Q2 '13: 180K Q3 '13: 723K Q4 '13: 769K Q1 '14: -453K Q2 '14: -1.5M Q3 '14: -1.4M Q4 '14: -2.9M Q1 '15: 995K Q2 '15: -2.1M Q3 '15: -1.1M Q4 '15: -2M Q1 '16: -504K Q2 '16: 517K Q3 '16: -41K Q4 '16: 51K Q1 '17: -466K Q2 '17: 3.3M Q3 '17: -1.8M Q4 '17: -507K Q1 '18: -120K Q2 '18: 359K Q3 '18: 289K Q4 '18: 837K Q1 '19: 780K Q2 '19: 559K Q3 '19: 422K Q4 '19: 983K Q1 '20: -1.9M Q2 '20: -2.2M Q3 '20: -2.4M Q4 '20: -1.6M Q1 '21: -3.4M Q2 '21: -6.8M Q3 '21: -6.4M Q4 '21: -6.8M Q1 '22: -5.4M Q2 '22: -4M Q3 '22: -6.1M Q4 '22: -5.4M Q1 '23: -6M Q2 '23: -3.9M Q3 '23: -5.8M Q4 '23: -4.7M Q1 '24: -3.7M Q2 '24: -2.3M Q3 '24: -6.3M Q4 '24: -3.5M Q1 '25: -2.1M Q2 '25: -2.5M Q3 '25: -1.3M Q4 '25: -1.1M Q1 '26: -2.3M Q2 '26: -4.2M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q4 '10: 297K Q1 '11: 422K Q2 '11: -665K Q3 '11: -358K Q4 '11: -419K Q1 '12: -150K Q2 '12: -72K Q3 '12: 250K Q4 '12: 902K Q1 '13: 43K Q2 '13: 53K Q3 '13: 549K Q4 '13: 84K Q1 '14: -775K Q2 '14: -1.7M Q3 '14: -1.6M Q4 '14: -3.2M Q1 '15: 780K Q2 '15: -2.4M Q3 '15: -1.4M Q4 '15: -2.2M Q1 '16: -681K Q2 '16: 403K Q3 '16: -56K Q4 '16: -70K Q1 '17: -563K Q2 '17: 3M Q3 '17: -2M Q4 '17: -673K Q1 '18: -289K Q2 '18: 248K Q3 '18: 278K Q4 '18: 480K Q1 '19: 739K Q2 '19: 521K Q3 '19: 390K Q4 '19: 966K Q1 '20: -1.9M Q2 '20: -2.2M Q3 '20: -2.4M Q4 '20: -1.7M Q1 '21: -3.4M Q2 '21: -6.8M Q3 '21: -6.4M Q4 '21: -7M Q1 '22: -5.5M Q2 '22: -4.2M Q3 '22: -6.2M Q4 '22: -5.5M Q1 '23: -6M Q2 '23: -3.9M Q3 '23: -5.8M Q4 '23: -4.7M Q1 '24: -3.8M Q2 '24: -2.5M Q3 '24: -6.3M Q4 '24: -3.5M Q4 '25: -1.2M Q1 '26: -2.3M Q2 '26: -4.2M Q3 '11 Q3 '13 Q3 '15 Q3 '17 Q3 '19 Q3 '21 Q3 '23 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '10: 60.2K Q3 '10: 60.8M Q2 '11: 60.4K Q3 '11: 60.4M Q1 '12: 64.5K Q2 '12: 70.5K Q3 '12: 71.4K Q4 '12: 70.6K Q3 '13: 71.2K Q3 '17: 2.5M Q3 '18: 2.9M Q3 '19: 2.9M Q1 '20: 17.5M Q2 '20: 17.6M Q3 '20: 17.6M Q1 '21: 27.8K Q2 '21: 42.4M Q3 '21: 2.5M Q1 '22: 2.7M Q2 '22: 2.9M Q3 '22: 2.9M Q1 '23: 5.1M Q2 '23: 5.3M Q3 '23: 5.4M Q1 '24: 5.4M Q2 '24: 361K Q3 '24: 361K Q1 '25: 142K Q2 '25: 207K Q3 '25: 8.2M Q1 '26: 792K Q2 '26: 1.2M Q3 '11 Q4 '12 Q3 '19 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-120.00 -80.00 -40.00 0.00 40.00 80.00 120.00 Q4 '13: -0.01 Q1 '14: -0.01 Q2 '14: -0.03 Q3 '14: -0.04 Q4 '14: -0.06 Q1 '15: -0.07 Q2 '15: -1.48 Q3 '15: -2.20 Q4 '15: -2.72 Q1 '16: -3.27 Q2 '16: -2.30 Q3 '16: -1.88 Q4 '16: -1.54 Q1 '17: -1.01 Q2 '17: -0.62 Q3 '17: -0.38 Q4 '17: -0.45 Q1 '18: -0.57 Q2 '18: -0.55 Q3 '18: -0.40 Q4 '18: -0.10 Q1 '19: -0.05 Q2 '19: -0.03 Q3 '19: -0.23 Q4 '19: -0.71 Q1 '20: -0.66 Q2 '20: -0.75 Q3 '20: -0.74 Q4 '20: -0.41 Q1 '22: -37.59 Q2 '22: -38.51 Q3 '22: -6.97 Q4 '22: -8.17 Q1 '23: -5.73 Q2 '23: -5.42 Q3 '23: -3.96 Q4 '23: -4.08 Q1 '24: -4.25 Q2 '24: -18.74 Q3 '24: -91.41 Q4 '24: -48.96 Q1 '25: -105.49 Q2 '25: -105.34 Q3 '25: -31.79 Q1 '14 Q3 '15 Q1 '17 Q3 '18 Q1 '20 Q3 '22 Q1 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.